Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Neurology and Therapy Année : 2020

Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment

Résumé

Cladribine is an oral synthetic purine analog that depletes lymphocytes and induces a dose-dependent reduction of T and B cells. It was approved for the therapy of highly active relapsing-remitting multiple sclerosis. Given cladribine's mechanism of action, an increased risk of malignancies was suspected from the number of cancers that occurred in the 3.5 mg/kg-treated arm (CLARITY study). We showed that cladribine inhibits cell proliferation on three melanoma cell lines tested, irrespectively of their mutational oncogenic status and invasive/metastatic potential. Aggregated safety data demonstrated that the risk of melanoma is not confirmed.
Fichier principal
Vignette du fichier
Lebrun-Frenay2020_Article_EffectsOnMelanomaCellLinesSugg.pdf (562.9 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

inserm-02914268 , version 1 (11-08-2020)

Identifiants

Citer

Christine Lebrun-Frenay, Ilona Berestjuk, Mikael Cohen, Sophie Tartare-Deckert. Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment. Neurology and Therapy, 2020, Online ahead of print. ⟨10.1007/s40120-020-00204-5⟩. ⟨inserm-02914268⟩
93 Consultations
58 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More